Key result
A patient with antithrombin-III deficiency exhibited a diminished anticoagulant response to heparin during cardiopulmonary bypass, highlighting implications for managing heparin rebound.
Case Report (n=1)
Highlights the clinical evaluation and management of AT-III deficiency manifesting as heparin resistance during cardiopulmonary bypass.
Answers are grounded in this paper and cite their sources.
Clinicians should consider AT-III deficiency in unexplained heparin resistance during CPB; single case leaves open whether monitoring or supplementation improves outcomes.
A case of antithrombin-III (AT-III) deficiency was diagnosed on the basis of a diminished anticoagulant effect following the administration of heparin for cardiopulmonary bypass. The clinical evaluation and interpretation of a diminished response to heparin is discussed, as are considerations relative to the treatment of AT-III deficient persons whose disorder is not manifest until they are already anesthetized for cardiovascular bypass. The implications of AT-III deficiency relative to the mechanism of heparin rebound are also discussed.
No takes yet. Share an insight, caveat, or question.
Soloway et al. (1980) conducted a case report in Antithrombin-III (AT-III) deficiency (n=1). Heparin was evaluated on Anticoagulant effect. A patient with antithrombin-III deficiency exhibited a diminished anticoagulant response to heparin during cardiopulmonary bypass, highlighting implications for managing heparin rebound.
Synapse has enriched 10 related papers. Consider them for comparative context: